Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Standard Biotools (LAB) Shares Outstanding (2016 - 2026)

Standard Biotools has reported Shares Outstanding over the past 16 years, most recently at $405.0 million for Q4 2025.

  • Quarterly Shares Outstanding rose 2.23% to $405.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $405.0 million through Dec 2025, up 2.23% year-over-year, with the annual reading at $405.0 million for FY2025, 2.23% up from the prior year.
  • Shares Outstanding was $386.4 million for Q4 2025 at Standard Biotools, down from $402.2 million in the prior quarter.
  • Over five years, Shares Outstanding peaked at $402.2 million in Q3 2025 and troughed at $75.0 million in Q1 2021.
  • The 5-year median for Shares Outstanding is $82.3 million (2023), against an average of $204.0 million.
  • Year-over-year, Shares Outstanding plummeted 68.05% in 2024 and then soared 1425.37% in 2025.
  • A 5-year view of Shares Outstanding shows it stood at $76.9 million in 2021, then grew by 3.88% to $79.9 million in 2022, then increased by 4.33% to $83.4 million in 2023, then soared by 375.16% to $396.1 million in 2024, then rose by 2.23% to $405.0 million in 2025.
  • Per Business Quant, the three most recent readings for LAB's Shares Outstanding are $405.0 million (Q4 2025), $402.2 million (Q3 2025), and $400.3 million (Q2 2025).